KR102626669B1 - 질환의 예방 및 치료를 위한 화합물 및 이의 용도 - Google Patents

질환의 예방 및 치료를 위한 화합물 및 이의 용도 Download PDF

Info

Publication number
KR102626669B1
KR102626669B1 KR1020197036413A KR20197036413A KR102626669B1 KR 102626669 B1 KR102626669 B1 KR 102626669B1 KR 1020197036413 A KR1020197036413 A KR 1020197036413A KR 20197036413 A KR20197036413 A KR 20197036413A KR 102626669 B1 KR102626669 B1 KR 102626669B1
Authority
KR
South Korea
Prior art keywords
group
substituted
disease
galectin
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197036413A
Other languages
English (en)
Korean (ko)
Other versions
KR20200016246A (ko
Inventor
엘리제 조머
피터 쥐. 트래버
라파엘 니어
샤론 쉑터
조셉 엠. 존슨
라이언 조지
Original Assignee
갈랙틴 사이언시즈, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈랙틴 사이언시즈, 엘엘씨 filed Critical 갈랙틴 사이언시즈, 엘엘씨
Publication of KR20200016246A publication Critical patent/KR20200016246A/ko
Application granted granted Critical
Publication of KR102626669B1 publication Critical patent/KR102626669B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H99/00—Subject matter not provided for in other groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
KR1020197036413A 2017-05-12 2018-05-11 질환의 예방 및 치료를 위한 화합물 및 이의 용도 Active KR102626669B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762505544P 2017-05-12 2017-05-12
US62/505,544 2017-05-12
PCT/US2018/032349 WO2018209255A1 (en) 2017-05-12 2018-05-11 Compounds for the prevention and treatment of diseases and the use thereof

Publications (2)

Publication Number Publication Date
KR20200016246A KR20200016246A (ko) 2020-02-14
KR102626669B1 true KR102626669B1 (ko) 2024-01-17

Family

ID=64105444

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197036413A Active KR102626669B1 (ko) 2017-05-12 2018-05-11 질환의 예방 및 치료를 위한 화합물 및 이의 용도

Country Status (12)

Country Link
US (2) US11576924B2 (https=)
EP (1) EP3621973A4 (https=)
JP (1) JP7204676B2 (https=)
KR (1) KR102626669B1 (https=)
CN (1) CN110869378B (https=)
AU (1) AU2018265571B2 (https=)
BR (1) BR112019023722A2 (https=)
CA (1) CA3062648A1 (https=)
IL (1) IL270469B2 (https=)
MX (1) MX392945B (https=)
WO (1) WO2018209255A1 (https=)
ZA (1) ZA201908165B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210100139A (ko) 2018-12-06 2021-08-13 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3의 소분자 억제제
CA3122321A1 (en) * 2018-12-27 2020-07-02 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides
EP3947407B1 (en) 2019-03-26 2024-06-12 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US12269819B2 (en) 2019-04-10 2025-04-08 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
WO2021028323A1 (en) 2019-08-09 2021-02-18 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
JP2023508363A (ja) * 2019-12-24 2023-03-02 グリコミメティクス， インコーポレイテッド ガレクチン－３阻害性ｃ－グリコシドケトン、エーテル、およびアルコール
US12275720B2 (en) * 2020-05-05 2025-04-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US12286424B2 (en) 2020-05-11 2025-04-29 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
KR20230018431A (ko) 2020-05-28 2023-02-07 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3 억제제
US12312362B2 (en) 2020-10-06 2025-05-27 Idorsia Pharmaceuticals Ltd Spiro derivatives of Alpha-D-galactopyranosides
EP4237419A1 (en) 2020-11-02 2023-09-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
CN116806219A (zh) * 2021-02-09 2023-09-26 爱杜西亚药品有限公司 羟基杂环烷-氨甲酰基衍生物
RS67032B1 (sr) * 2021-03-03 2025-08-29 Idorsia Pharmaceuticals Ltd Alfa-d-galaktopiranozidni derivati supstituisani triazolil-metilom

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028318A1 (en) 1996-12-20 1998-07-02 Oxford Glycosciences (Uk) Limited Therapeutic compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812681A1 (de) * 1988-04-16 1989-11-02 Bayer Ag Substituierte n-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
SE0401301D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
GB0501008D0 (en) * 2005-01-18 2005-02-23 Amura Therapeutics Ltd Method of producing conjugate vaccines
US9427449B2 (en) 2005-08-26 2016-08-30 Econugenics, Inc. Binding of galectin-3 by low molecular weight pectin
EP2081961A2 (en) 2006-11-15 2009-07-29 The Brigham and Women's Hospital, Inc. Therapeutic uses of tim-3 modulators
ES2543063T3 (es) 2008-05-16 2015-08-14 Galecto Biotech Ab Nueva síntesis de inhibidores de galactósidos
ES2652488T3 (es) * 2009-04-28 2018-02-02 Galecto Biotech Ab Nuevos inhibidores de galactósidos de galectinas
CN102576028A (zh) 2009-08-25 2012-07-11 保函医药公司 半乳凝集素-3和心脏再同步疗法
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
CA2794066C (en) 2012-10-31 2017-02-28 Neil Henderson Galactoside inhibitor of galectins
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
MX360979B (es) 2011-09-16 2018-11-22 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
MX363923B (es) 2011-12-28 2019-04-08 Galectin Therapeutics Inc Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas.
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
DK2906227T3 (en) 2012-10-10 2018-12-10 Galectin Therapeutics Inc GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy
CN104755088A (zh) 2012-10-31 2015-07-01 格莱克特生物技术公司 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用
EP2919802A4 (en) 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
AR099707A1 (es) 2014-03-10 2016-08-10 La Jolla Pharma Co Composiciones y métodos para tratar trastornos renales
WO2015155207A1 (en) 2014-04-08 2015-10-15 Galecto Biotech Ab Galactoside inhibitors for the treatment of alpha-synucleinopthies
JP6735680B2 (ja) 2014-07-09 2020-08-05 ガレクト バイオテック エービー ガレクチンの新規ハイブリッドガラクトシド阻害剤
CA2970062C (en) 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
WO2017019770A1 (en) 2015-07-27 2017-02-02 Wayne State University Compositions and methods relating to galectin detection
CA3000924A1 (en) 2015-11-09 2017-05-18 Galecto Biotech Ab Novel galactoside inhibitors of galectins
MX394409B (es) * 2016-03-04 2025-03-24 Galectin Sciences Llc Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.
KR20200015528A (ko) 2017-05-12 2020-02-12 갈랙틴 사이언시즈, 엘엘씨 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028318A1 (en) 1996-12-20 1998-07-02 Oxford Glycosciences (Uk) Limited Therapeutic compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cell, 1994, 76, 597-598
Eur. J. Org. Chem., 2009, 3783-3789

Also Published As

Publication number Publication date
AU2018265571B2 (en) 2022-09-29
WO2018209255A1 (en) 2018-11-15
EP3621973A1 (en) 2020-03-18
IL270469A (https=) 2019-12-31
IL270469B2 (en) 2023-07-01
MX392945B (es) 2025-03-19
IL270469B1 (en) 2023-03-01
KR20200016246A (ko) 2020-02-14
US11576924B2 (en) 2023-02-14
CN110869378B (zh) 2023-10-13
CA3062648A1 (en) 2018-11-15
JP2020519625A (ja) 2020-07-02
ZA201908165B (en) 2023-07-26
AU2018265571A1 (en) 2019-12-05
CN110869378A (zh) 2020-03-06
US20230132265A1 (en) 2023-04-27
US20200155586A1 (en) 2020-05-21
EP3621973A4 (en) 2021-10-27
BR112019023722A2 (pt) 2020-05-26
JP7204676B2 (ja) 2023-01-16
MX2019013537A (es) 2020-02-13

Similar Documents

Publication Publication Date Title
KR102626669B1 (ko) 질환의 예방 및 치료를 위한 화합물 및 이의 용도
KR20200015528A (ko) 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도
CA3080128A1 (en) Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
KR102692840B1 (ko) 의학적 장애의 예방 및 치료를 위한 화합물 및 이의 용도
US20230127345A1 (en) Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
WO2013110704A1 (en) Novel galactoside inhibitors of galectins
WO2021023512A1 (en) Bifunctional compound and its use in immunotherapy
Miranda et al. Bifunctional compound and its use in immunotherapy
BR112018067693B1 (pt) Selenogalactosídeos, seus usos, e composição

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191209

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210510

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230224

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230828

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230224

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230828

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230523

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210510

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20231116

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20231011

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230828

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230523

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210510

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240115

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240115

End annual number: 3

Start annual number: 1

PG1601 Publication of registration